Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

NCT01217229 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

DRUG: PLX3397

Sponsor

Daiichi Sankyo

Collaborators

[object Object]